Abstract

Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice Tumour necrosis factor inhibitors (TNFi) are effective in the majority of patients with rheumatoid arthritis (RA),1 however, an important reason for non-response is low drug level due to immunogenicity.2 To our knowledge, no data collected during a prospective observational study is currently available regarding the relationship between golimumab level, immunogenicity and response in RA. This prospective observational cohort consisted of 37 con-secutive adult patients with RA, according to the American College of Rheumatology 1987 revised criteria,3 in whom goli-mumab 50 mg subcutaneously once monthly was initiated according to the judgment of the rheumatologist, and who wer